Teleflex Highlights UroLift and Barrigel Data at Urological Congresses Amid Divestiture Plans
Event summary
- Teleflex presented new clinical data for UroLift™ System and Barrigel™ rectal spacer at AUA 2026 and ESTRO 2026 congresses.
- CLEAR RCT study showed UroLift™ System patients had significantly better catheter independence and early patient experience compared to Rezūm™ patients.
- Barrigel™ rectal spacer demonstrated sustained Grade 2+ toxicity reduction through three years in prostate cancer patients.
- Teleflex's Interventional Urology business unit is preparing for divestiture in the second half of 2026.
The big picture
Teleflex's presentation of new clinical data underscores its commitment to patient-centered outcomes in urology, even as it prepares to divest the Interventional Urology business unit. The focus on long-term toxicity reduction and early patient experience advantages aligns with broader industry trends toward minimally invasive and durable solutions in prostate health. The divestiture reflects Teleflex's strategic shift toward high-acuity hospital markets, potentially reshaping its competitive landscape in urological care.
What we're watching
- Divestiture Impact
- How the planned divestiture of the Interventional Urology business unit will affect Teleflex's focus on critical care and high-acuity hospital end-markets.
- Market Adoption
- Whether the sustained clinical benefits of Barrigel™ rectal spacer will drive broader adoption in prostate cancer radiation therapy.
- Competitive Positioning
- The pace at which UroLift™ System can maintain its competitive edge against other minimally invasive surgical therapies for BPH.
Related topics